SEC Form 4 · accession 0001209191-15-010444
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua S Boger
Director
Period of report
Feb 4, 2015
Accepted (ET)
Feb 6, 2015 · 5:43 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 4, 2015 | M | 1,300 | $17.16 | A | 340,195 | D | |
| Common Stock | Feb 4, 2015 | M | 4,400 | $35.64 | A | 344,595 | D | |
| Common StockF2,F3 | Feb 4, 2015 | S | 500 | $105.34 | D | 344,095 | D | |
| Common StockF3,F4 | Feb 4, 2015 | S | 300 | $106.51 | D | 343,795 | D | |
| Common StockF3,F5 | Feb 4, 2015 | S | 500 | $108.18 | D | 343,295 | D | |
| Common StockF3,F6 | Feb 4, 2015 | S | 3,700 | $109.30 | D | 339,595 | D | |
| Common StockF3,F7 | Feb 4, 2015 | S | 700 | $110.15 | D | 338,895 | D | |
| Common Stock | holding | — | — | — | 13,286 | I | 401(k) | |
| Common StockF8 | holding | — | — | — | 172,589 | I | Common Stock held in trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F9 | $17.16 | Feb 4, 2015 | M | 1,300 | D | — | Jul 19, 2015 | Common Stock | 1,300 | 30,400 | D |
| Stock Option (right to buy)F9 | $35.64 | Feb 4, 2015 | M | 4,400 | D | — | Feb 1, 2016 | Common Stock | 4,400 | 525,200 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $105.34 (range $104.86 to $105.70).
- F3Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Open market sales reported on this line occurred at a weighted average price of $106.51 (range $106.14 to $106.76).
- F5Open market sales reported on this line occurred at a weighted average price of $108.18 (range $107.55 to $108.41).
- F6Open market sales reported on this line occurred at a weighted average price of $109.30 (range $108.78 to $109.77).
- F7Open market sales reported on this line occurred at a weighted average price of $110.15 (range $109.81 to $110.56).
- F8Common stock held in grantor retained annuity trusts.
- F9Fully vested.